Clinical Trial Detail

NCT ID NCT03728335
Title Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors City of Hope Medical Center
Indications

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: adult senior

Additional content available in CKB BOOST